CClinicalTrials.gg
CompletedNCT03498586Updated Apr 5, 2022

Half-normal Saline in Atrial Fibrillation Ablation

An interventional study of Half-normal saline and Normal saline in Atrial Fibrillation, sponsored by Texas Cardiac Arrhythmia Research Foundation. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-04-05.

Sponsored by Texas Cardiac Arrhythmia Research Foundation · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The study evaluates the use of half-normal saline as an irrigant for open-irrigated catheters during atrial fibrillation ablation. By increasing the efficacy of radiofrequency energy-mediated lesion formation, half-normal saline has the potential to reduce procedural times and improved acute and long-term outcomes.

02

Conditions studied

  • Atrial Fibrillation

Browse trials for

03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • male or female between 18 and 75 years of age at the time of enrollment
  • undergoing first-time radiofrequency ablation for atrial fibrillation
  • written informed consent obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study

Exclusion criteria

Exclusion criteria

  • robotic-guided atrial fibrillation ablation
  • baseline hyponatremia (serum sodium level \< 135 mEq/L)
  • pregnant, breastfeeding, or unwilling to practice birth control during participation in the study
  • presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    Half-normal saline

    Drug: Half-normal saline

  • Active comparator
    Normal saline

    Drug: Normal saline

Interventions

  • DrugHalf-normal saline

    Use of half-normal saline as an irrigant for open-irrigated ablation catheters

  • DrugNormal saline

    Use of normal saline as an irrigant for open-irrigated ablation catheters

05

What researchers measure

Primary outcomes

  1. total radiofrequency ablation time, and total procedure time

    Time frame: intraprocedural

  2. acute pulmonary veins, and left atrial appendage (if applicable) reconnection

    Time frame: intraprocedural

  3. freedom from atrial tachycardia/atrial fibrillation > 30 seconds without antiarrhythmic drugs

    Time frame: 1 year

Secondary outcomes

  1. freedom from atrial tachycardia/atrial fibrillation > 30 seconds with or without antiarrhythmic drugs

    Time frame: 1 year

  2. long-term pulmonary veins, left atrial appendage (if applicable), and coronary sinus (if applicable) reconnection

    Time frame: in case of a repeat procedure performed during the study follow-up (an average of 1 year)

Other outcomes

  1. procedure-related complications

    pericardial effusion due to cardiac perforation or pericarditis, transient ischemic attack/stroke, systemic embolism, phrenic nerve injury, pulmonary vein stenosis, atrio-esophageal fistula, death

    Time frame: periprocedural (at the time of the procedure and up to 1 month)

  2. hyponatremia

    serum sodium level \< 135 mEq/L

    Time frame: periprocedural (at the time of the procedure and up to 1 month)

06

Study locations

2 sites
  • Texas Cardiac Arrhythmia Institute, St. David's Medical Center
    Austin, Texas 78705, United States
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
07

Registry details

Key details

Study ID
NCT03498586
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Responsible party
Andrea Natale (Executive Medical Director, Texas Cardiac Arrhythmia Research Foundation) — Principal investigator
First posted
Apr 13, 2018
Start date
May 2, 2018
Primary completion
May 2, 2019
Completion
May 2, 2020
Last update
Apr 5, 2022

Study contacts

Andrea Natale, MD
principal investigator · Texas Cardiac Arrhythmia Institute, St. David's Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion